EpiVacCorona
EpiVacCorona is a peptide-based vaccine against COVID-19 developed by the Vector Institute in Russia. It was authorized for emergency use in Russia in October 2020, following Phase I and II trials. As of March 2021, Phase III trials are ongoing.
Development
The Vector Institute, also known as the State Research Centre of Virology and Biotechnology, began development of EpiVacCorona in early 2020, following the global outbreak of the SARS-CoV-2 virus. The vaccine is based on synthetic peptide antigens of SARS-CoV-2 proteins, conjugated to a carrier protein and administered with an adjuvant.
Clinical Trials
EpiVacCorona underwent Phase I and II clinical trials in 2020. The trials involved a total of 100 participants and reportedly showed the vaccine to be safe and effective. However, the results have not been published in a peer-reviewed journal, leading to calls for greater transparency.
Phase III trials began in November 2020 and are expected to involve 3,000 participants. Preliminary results are expected in early 2021.
Efficacy
The Vector Institute has claimed that EpiVacCorona is 100% effective, based on the results of the Phase I and II trials. However, these claims have been met with skepticism due to the lack of published data.
Authorization
EpiVacCorona was granted emergency use authorization in Russia in October 2020, making it the second COVID-19 vaccine to be authorized in the country, after Sputnik V.
See Also
Ad. Transform your life with W8MD's
GLP-1 weight loss injections special from $29.99 with insurance
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
